345 results on '"P.I. Karakiewicz"'
Search Results
2. Age and Gleason score upgrading between prostate biopsy and radical prostatectomy. Is this still true in the mp-MRI era?
3. Should we target all visible areas at mpMRI suspicious for clinically significant prostate cancer in addition to the index lesion? Results from a two-institution series
4. Comparison between small renal masses 0–2cm vs. 2.1–4 cm in size: a population-based study
5. Prognostic differences in patients with T1a renal cell carcinoma according to clinical size
6. Pre-operative risk calculator of the probability of completing nephron-sparing surgery for kidney cancer: The key role of surgical experience and approach
7. Focal therapy for prostate cancer: do apical lesions correlate with worse outcomes?
8. Changing patterns and predictors of salvage radiation therapy use over time in patients treated for post-prostatectomy biochemical recurrence: a trend analysis over a 20-year period from a multi institutional series
9. A positive PSMA PET/CT Predicts more aggressive disease progression in patients with biochemical recurrence after radical prostatectomy
10. Long-term outcomes of clinically node-positive prostate cancer patients treated with radical prostatectomy as part of a multimodal treatment: patterns of recurrence and impact on competing-risk mortality
11. Radical prostatectomy versus radiotherapy in M1a and low volume M1b prostate cancer patients: an indirect comparison with the STAMPEDE trial arm H
12. The impact of persistently elevated PSA levels on progression and survival of patients undergoing cytoreductive radical prostatectomy for oligometastatic prostate cancer
13. A prospective, randomized, phase 3 trial assessing the impact of Early Dorsal Venous Complex (EDVC) ligation on urinary continence recovery after robot-assisted radical prostatectomy. results of an interim analysis on early post-operative outcomes
14. External validation of the 2019 Briganti nomogram for the identification of prostate cancer patients who should be considered for an extended pelvic lymph node dissection
15. The relative drop of PSA values after androgen deprivation therapy is a useful parameter to select the best candidate for cytoreductive radical prostatectomy among patients with oligometastatic prostate cancer: an external validation study
16. Higher cancer mortality in rural upper urinary tract urothelial carcinoma patients
17. The effect of age on cancer-specific mortality in patients with prostate cancer: A population-based study across all stages
18. Synchronous metastases rates in T1 renal cell carcinoma: A SEER-based study
19. The clinical value of the urokinase-plasminogen activator system (uPA) in patients with radical cystectomy (RC) for bladder cancer
20. External validation of the 2019 Briganti nomogram for the identification of prostate cancer patients who should be considered for an extended pelvic lymph node dissection
21. Should we target all visible areas at mp-MRI suspicious for clinically significant prostate cancer in addition to the index lesion? Results from a two-institution series
22. A positive PSMA PET/CT predicts more aggressive disease progression in patients with biochemical recurrence after radical prostatectomy
23. Initial negative multi-parametric MRI with concomitant negative biopsy: Are true negative findings confirmed over time? Results from a single institution series
24. Distribution of histological subtypes and tumor grade according to tumor size in T1-T2 surgically treated renal cell carcinoma
25. State-of-the-art weakly supervised automated classification of prostate cancer tissue microarrays via deep learning: Can sufficient accuracy be achieved without manual patch level annotation?
26. Differences in survival of clear cell metastatic renal cell carcinoma patients according to partial vs. radical nephrectomy
27. Pre-operative risk calculator for the probability of completing surgery for kidney cancer: The key role of tumour complexity and surgical experience
28. Survival of testicular pure teratoma vs. mixed germ cell tumor patients across all stages
29. Carboplatin induction chemotherapy in clinically lymph node-positive bladder cancer
30. Frailty Index in predicting surgical outcomes after partial nephrectomy in patients with renal cell carcinoma
31. Lymphovascular invasion predicts lymph node involvement in patients with renal cell carcinoma
32. The current role of precision surgery in oligometastatic prostate cancer
33. Adjuvant therapy in intermediate-risk non-muscle-invasive bladder cancer
34. Lawton instrumental activities of daily living scale identifies patients at high-risk of adverse outcomes after kidney surgery for renal cancer: A prospective clinical study
35. Contemporary conditional cancer-specific survival rates in stage III non-seminoma testis cancer patients: A population-based analysis
36. Adenocarcinoma of the bladder: Assessment of survival benefit associated with radical cystectomy and comparison with urothelial bladder cancer
37. Effect of chemotherapy in sarcomatoid bladder cancer patients treated with radical cystectomy
38. Regional differences in stage distribution and rates of treatment for adrenocortical carcinoma across United States SEER registries
39. The impact of frailty status on surgical outcomes after robot-assisted radical prostatectomy - a prospective assessment using a standardized collection system for perioperative outcomes
40. Effect of chemotherapy in sarcomatoid bladder cancer patients treated with radical cystectomy
41. The effect of age on cancer-specific mortality in T1a stage renal cell carcinoma patients: a population-based study across all treatment’s modalities
42. The learning curve of radical nephrectomy for kidney cancer: implications for surgical training
43. A more extended pelvic lymph node dissection decreases recurrence rates in selected prostate cancer patients undergoing radical prostatectomy
44. The association of type and number of d’amico high-risk criteria with rates of pathologically non organ confined prostate cancer
45. Survival after radical prostatectomy vs. radiation therapy in clinical node-positive prostate cancer
46. Pembrolizumab outperforms tyrosine kinase inhibitors in the adjuvant therapy of patients with high-risk renal cell carcinoma: A systematic review and network meta-analysis
47. When can we de-intensify treatments in ISUP Grade Group 5 prostate cancer? Long-term results of a single center, high volume series
48. The anatomical location of lymphadenopathies at imaging predicts the risk of lymph node invasion at final pathology in patients with renal cell carcinoma
49. Risks and benefits of partial nephrectomy with limited or without ischemia time
50. Radical vs. partial cystectomy for urachal carcinoma: A population-based analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.